Alemtuzumab against CD52 gained considerable efficacy [34, 35], and Pembrolizumab against programmed cell death protein-1 (PD-1) showed activity among SS patients in clinical trials [36, 37]. The gene discussed is PDCD1; the disease is synovial sarcoma.